Who Paid My Doc
Syeda Hamadani
Allergy & Immunology Lawrenceville, GA Medical Doctor
NPI 1710246848 CMS profile 2789778
301 Gwinnett Dr, Lawrenceville, GA 30046
General payments
$5,855
Research payments
$0
Ownership & investment interest
$0
Through program year 2022, Syeda Hamadani of Lawrenceville, GA is reported in the CMS Open Payments database as having received $5,855 across 116 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 60th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $109 | 5 | |
| 2021 | General | $523 | 23 | |
| 2020 | General | $3,299 | 34 | |
| 2019 | General | $1,924 | 54 |
Beside peers
- Syeda Hamadani
- Allergy & Immunology median
- Middle half of Allergy & Immunology
- National median
In program year 2025, general payments to Syeda Hamadani were reported at $0. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.
Show as a table
| Year | Syeda Hamadani | Allergy & Immunology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,924 | $594 | $163–$1,512 | $163 |
| 2020 | $3,299 | $426 | $106–$1,233 | $114 |
| 2021 | $523 | $638 | $157–$1,708 | $132 |
| 2022 | $109 | $790 | $205–$1,961 | $149 |
| 2023 | $0 | $852 | $220–$2,147 | $160 |
| 2024 | $0 | $865 | $203–$2,267 | $164 |
| 2025 | $0 | $1,140 | $272–$2,892 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 10 drugsPart D claims
295
Drug cost
$89,048
Branded share of claims
35.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Dupixent Pen Dupilumab | Brand | 15 | $52,639 | |
| Breyna Budesonide/Formoterol Fumarate | Brand | 31 | $17,338 | |
| Spiriva Respimat Tiotropium Bromide | Brand | 23 | $10,338 | |
| Wixela Inhub Fluticasone Propion/Salmeterol | Brand | 13 | $2,483 | |
| Alvesco Ciclesonide | Brand | 12 | $2,470 | |
| Ipratropium Bromide | Generic | 63 | $1,562 | |
| Azelastine Hcl | Generic | 81 | $1,551 | |
| Montelukast Sodium | Generic | 29 | $318 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 12 | $240 | |
| Prednisone | Generic | 16 | $108 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.
Records
116 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Allergy & Immunology in Georgia
Practitioners in the same specialty and state, ranked by reported value.
All Allergy & Immunology
Everyone recorded under this specialty, nationwide.
Doctors in Georgia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.